Hey Mozz - Amgen just announced a takeover of a phase 3 ready bio on the oncology field. One of the reasons stated for the takeover was to maintain a lead in Oncology field.
Upon further reading, Amgen's blockbuster drug is Enbrel - have you written about Enbrel before? it's a RA drug and I just wonder if an OA drug may just fit the portfolio of a company like Amgen...perhaps compliments their RA offering. Regardless, Enbrel just might provide some insight to the pathway Zilosul could potentially take one day - in terms of cost to patient and revenues it could generate.
PAR - Deal me in, page-83
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.5¢ |
Change
-0.005(1.79%) |
Mkt cap ! $96.19M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 28.5¢ | 27.0¢ | $55.31K | 200.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1072 | 27.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.5¢ | 3289 | 1 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |